Cargando…

New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma

The anti-epileptic drug valproic acid is also under trial as an anti-cancer agent due to its histone deacetylase (HDAC) inhibitory properties. However, the effects of valproic acid (VPA) are limited and concentrations required for exerting anti-neoplastic effects in vitro may not be reached in tumou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wedel, S A, Sparatore, A, Soldato, P D, Al-Batran, S-E, Atmaca, A, Juengel, E, Hudak, L, Jonas, D, Blaheta, R A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2008
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514123/ https://www.ncbi.nlm.nih.gov/pubmed/18266964 http://dx.doi.org/10.1111/j.1582-4934.2008.00271.x

Ejemplares similares

Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis
por: Wedel, Steffen, et al.
Publicado: (2011)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Histone deacetylase inhibitors as novel anticancer therapeutics
por: Walkinshaw, D.R., et al.
Publicado: (2008)

Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells
por: Juengel, Eva, et al.
Publicado: (2009)

Resistance to the mTOR-inhibitor RAD001 elevates integrin α2- and β1-triggered motility, migration and invasion of prostate cancer cells
por: Tsaur, I, et al.
Publicado: (2012)

Intensified antineoplastic effect by combining an HDAC-inhibitor, an mTOR-inhibitor and low dosed interferon alpha in prostate cancer cells
por: Tsaur, Igor, et al.
Publicado: (2015)

Therapeutic Strategies to Enhance the Anticancer Efficacy of Histone Deacetylase Inhibitors
por: Miller, Claudia P., et al.
Publicado: (2011)

Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies
por: Ellis, Leigh, et al.
Publicado: (2010)

Acetylation and Histone Deacetylase Inhibitors in Cancer
por: Kortenhorst, Madeleine S. Q., et al.
Publicado: (2006)

Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics
por: Chhabra, Saurabh
Publicado: (2017)

Clinical Toxicities of Histone Deacetylase Inhibitors
por: Subramanian, Srividya, et al.
Publicado: (2010)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Mechanism of histone deacetylases in cardiac hypertrophy and its therapeutic inhibitors
por: Han, Yu, et al.
Publicado: (2022)

A review of the therapeutic potential of histone deacetylase inhibitors in rhabdomyosarcoma
por: Selim, Omar, et al.
Publicado: (2023)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Cytostatic Action of Novel Histone Deacetylase Inhibitors in Androgen Receptor-Null Prostate Cancer Cells
por: Rana, Zohaib, et al.
Publicado: (2021)

Cross-communication between histone H3 and H4 acetylation and Akt-mTOR signalling in prostate cancer cells
por: Makarević, Jasmina, et al.
Publicado: (2014)

Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?
por: Nolan, L, et al.
Publicado: (2008)

Histone Deacetylase Inhibitors: The Epigenetic Therapeutics That Repress Hypoxia-Inducible Factors
por: Chen, Shuyang, et al.
Publicado: (2011)

Therapeutic effects of histone deacetylase inhibitors in a murine asthma model
por: Ren, Yuan, et al.
Publicado: (2016)

Histone Deacetylase Inhibitors: A Promising Therapeutic Alternative for Endometrial Carcinoma
por: Psilopatis, Iason, et al.
Publicado: (2021)

Histone deacetylase inhibitors as a novel therapeutic approach for pheochromocytomas and paragangliomas
por: MANTA, ASPASIA, et al.
Publicado: (2023)

Histone deacetylase inhibitors in multiple myeloma
por: Deleu, Sarah, et al.
Publicado: (2009)

Histone deacetylase inhibitors in Hodgkin lymphoma
por: Buglio, Daniela, et al.
Publicado: (2010)

Histone Deacetylase Inhibitors as Anticancer Drugs
por: Eckschlager, Tomas, et al.
Publicado: (2017)

The application of histone deacetylases inhibitors in glioblastoma
por: Chen, Rui, et al.
Publicado: (2020)

Histone Deacetylases and Their Inhibitors in Cancer Epigenetics
por: Hassell, Kelly N.
Publicado: (2019)

Histone Deacetylase Inhibitors Induce Epithelial-to-Mesenchymal Transition in Prostate Cancer Cells
por: Kong, Dejuan, et al.
Publicado: (2012)

Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer
por: Pramanik, Siddhartha Das, et al.
Publicado: (2022)

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
por: Yan, Wensheng, et al.
Publicado: (2012)

Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors
por: Lapierre, Marion, et al.
Publicado: (2016)

Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro
por: Freese, Kim, et al.
Publicado: (2019)

Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer
por: Alzoubi, Samer, et al.
Publicado: (2016)

Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer
por: Paller, Channing J, et al.
Publicado: (2014)

The Therapeutic Potential of Class I Selective Histone Deacetylase Inhibitors in Ovarian Cancer
por: Khabele, Dineo
Publicado: (2014)

Histone Deacetylase Inhibitors in Pediatric Brain Cancers: Biological Activities and Therapeutic Potential
por: Perla, Alexandre, et al.
Publicado: (2020)

Histone Deacetylase Inhibitors as Therapeutic Interventions on Cervical Cancer Induced by Human Papillomavirus
por: Lourenço de Freitas, Natália, et al.
Publicado: (2021)

Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma
por: Yelton, Caleb J., et al.
Publicado: (2018)

Enhancing the anti-angiogenic action of histone deacetylase inhibitors
por: Kuljaca, Selena, et al.
Publicado: (2007)

The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis
por: Conforti, Franco, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_a2i66jbcfbsf7g0lnp8le6kkm2